

CITATION REPORT

List of articles citing

Classification of current anticancer immunotherapies

DOI: 10.18632/oncotarget.2998
Oncotarget, 2014, 5, 12472-508.

Source: <https://exaly.com/paper-pdf/57483848/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
353	The expanding role of immunopharmacology: IUPHAR Review 16. 2015 , 172, 4217-27		17
352	The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. 2015 , 1,		78
351	A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. 2015 , 3, 48		21
350	Immunotherapies for bladder cancer: a new hope. 2015 , 25, 586-96		13
349	Immunotherapy for glioblastoma: concepts and challenges. 2015 , 28, 639-46		22
348	Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. <i>Oncotarget</i> , 2015 , 6, 26841-60	3.3	64
347	Immunogenic cell death. 2015 , 59, 131-40		125
346	Immunity, inflammation, and cancer: an eternal fight between good and evil. 2015 , 125, 3347-55		423
345	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. <i>Oncotarget</i> , 2015 , 6, 27160-75	3.75	39
344	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015 , 3, 467-89	5.3	23
343	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. 2015 , 6, 402		84
342	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. 2015 , 6, 588		239
341	Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. <i>Vaccines</i> , 2015 , 3, 771-802	5.3	9
340	CD5 as a Target for Immune-Based Therapies. 2015 , 35, 85-115		14
339	Combinatorial strategies for the induction of immunogenic cell death. 2015 , 6, 187		228
338	Type I interferons in anticancer immunity. 2015 , 15, 405-14		606
337	Immunotherapy for Head and Neck Squamous Cell Carcinoma. 2015 , 29, 1033-43		22

336	Autophagy, a major adaptation pathway shaping cancer cell death and anticancer immunity responses following photodynamic therapy. 2015 , 14, 1410-24	44
335	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. 2015 , 4, e1008814	68
334	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. 2015 , 4, e1008866	162
333	Cancer: Antibodies regulate antitumour immunity. 2015 , 521, 35-7	26
332	Hypermutation takes the driver's seat. 2015 , 7, 31	14
331	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. 2015 , 26, 2470-7	15
330	Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. 2015 , 4, e1058037	23
329	Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. 2015 , 11, 2645-2654	26
328	Natural and therapy-induced immunosurveillance in breast cancer. 2015 , 21, 1128-38	196
327	Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. 2015 , 4, e1008853	6
326	Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells. 2015 , 23, 656-71	25
325	Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. 2015 , 4, e1058597	48
324	Trial Watch: Adoptive cell transfer for oncological indications. 2015 , 4, e1046673	22
323	Trial watch: Naked and vectored DNA-based anticancer vaccines. 2015 , 4, e1026531	22
322	Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia. 2015 , 8, 75-92	22
321	Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. 2015 , 64, 1339-48	18
320	Tumor-Associated Macrophages. 2016 , 493-498	0
319	Improving the clinical impact of biomaterials in cancer immunotherapy. <i>Oncotarget</i> , 2016 , 7, 15421-43	3-3 43

318	Editorial: Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality. 2016 , 7, 110	16
317	Hypericin in the Light and in the Dark: Two Sides of the Same Coin. 2016 , 7, 560	91
316	The Role of Immunotherapy in Multiple Myeloma. 2016 , 9,	19
315	Muramyl dipeptide and anti-CD10 monoclonal antibody immunoconjugate enhances anti-leukemia immunity of T lymphocytes. 2016 , 124, 800-4	1
314	Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. 2016 , 197, 1477-88	24
313	Immunotherapy for genitourinary cancer: state of the art and new perspectives. 2016 , 27, 585-99	4
312	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. 2016 , 8, 1393-1404	7
311	Targeting the Microenvironment in Advanced Colorectal Cancer. 2016 , 2, 495-504	56
310	Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated vector for antigens delivery. 2016 , 3, 16033	10
309	STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. 2016 , 5, e1126063	10
308	The present status and future prospects of peptide-based cancer vaccines. 2016 , 28, 319-28	80
307	Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). 2016 , 11, 29-36	16
306	Current Challenges in Cancer Treatment. 2016 , 38, 1551-66	318
305	Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. 2016 , 15, 3058-70	38
304	Functional characterization of AMP-activated protein kinase signaling in tumorigenesis. 2016 , 1866, 232-251	30
303	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. 2016 , 5, e1214790	51
302	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. 2016 , 9, 89-104	113
301	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. 2016 , 4, 744-54	94

300	Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?. 2016 , 68, 134-147	69
299	Progress in Cancer Immunotherapy. 2016 ,	5
298	Mouse Models of Tumor Immunotherapy. 2016 , 130, 1-24	25
297	Adoptive Cellular Therapy (ACT) for Cancer Treatment. 2016 , 909, 169-239	10
296	Doubling the blockade for melanoma immunotherapy. 2016 , 5, e1106127	9
295	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. 2016 , 5, e1085147	94
294	Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. 2016 , 23, 938-51	84
293	Coordination of stress, Ca ²⁺ , and immunogenic signaling pathways by PERK at the endoplasmic reticulum. 2016 , 397, 649-56	14
292	Personalized chemotherapy of lung cancer: What the radiologist should know. 2016 , 97, 287-96	8
291	A Randomized Phase II/III Study of Naptumomab Estafenatox + IFN β versus IFN α in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. 2016 , 22, 3172-81	15
290	Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. 2016 , 5, e1145333	9
289	Calreticulin, a therapeutic target?. 2016 , 20, 1137-47	44
288	A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature. 2016 , 212, 491-9	20
287	Trial Watch-Oncolytic viruses and cancer therapy. 2016 , 5, e1117740	76
286	Molecular pathology in real time. 2016 , 35, 129-40	7
285	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. 2016 , 5, e1149673	99
284	MYC regulates the antitumor immune response through CD47 and PD-L1. 2016 , 352, 227-31	651
283	Tumor-associated macrophages and anti-tumor therapies: complex links. 2016 , 73, 2411-24	64

282	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. 2016 , 8, 4-31	36
281	First oncolytic virus approved for melanoma immunotherapy. 2016 , 5, e1115641	181
280	Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis. 2016 , 5, e1069938	41
279	Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. 2016 , 5, e1083669	42
278	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. 2016 , 5, e1088631	81
277	From T cell "exhaustion" to anti-cancer immunity. 2016 , 1865, 49-57	13
276	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. 2016 , 99, 87-96	48
275	More than a scaffold: Stromal modulation of tumor immunity. 2016 , 1865, 3-13	25
274	Biomarkers for immunotherapy in genitourinary malignancies. 2016 , 34, 205-13	14
273	Experimental animal modeling for immuno-oncology. 2017 , 173, 34-46	25
272	Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. 2017 , 37, 171-178	16
271	Applications of Immunogenomics to Cancer. 2017 , 168, 600-612	129
270	Identifying the optimal anticancer targets from the landscape of a cancer-immunity interaction network. 2017 , 19, 7642-7651	18
269	Vaccines and Immunostimulants. 2017 , 1-22	0
268	Novel immune checkpoint blocker to treat Merkel cell carcinoma. 2017 , 6, e1315496	1
267	Trial watch: Dendritic cell-based anticancer immunotherapy. 2017 , 6, e1328341	70
266	Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. 2017 , 7, 1217	75
265	Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?. 2017 , 3, 319-325	41

264	(Very) Early technology assessment and translation of predictive biomarkers in breast cancer. 2017 , 52, 117-127	7
263	Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. 2017 , 18, 1443-1455	20
262	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. 2017 , 134, 297-316	17
261	Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma. 2017 , 9, 319-329	3
260	Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents. 2017 , 330, 115-156	16
259	A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients. 2017 , 191, 35-39	11
258	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. 2017 , 6, e1386829	143
257	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <i>European Journal of Immunology</i> , 2017 , 47, 1584-1797	6.1 359
256	Biomarker Panels and Contemporary Practice in Clinical Trials of Targeted Therapy. 2017 , 507-523	
255	Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. 2017 , 280, 126-148	178
254	Mono- and Di-Alkylation Processes of DNA Bases by Nitrogen Mustard Mechlorethamine. 2017 , 18, 3390-3401	3
253	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. 2017 , 6, e1371896	33
252	Trial watch: Immune checkpoint blockers for cancer therapy. 2017 , 6, e1373237	53
251	Nanomaterials for cancer immunotherapy. 2017 , 148, 16-30	173
250	Chimiothérapies personnalisées du cancer bronchique : ce que le radiologue doit connaître. 2017 , 98, 146-156	
249	Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. 2017 , 32, 300-312	35
248	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. 2017 , 176, 1163-1172	9
247	Personalized Medicine. 2017 , 101-133	

246	Trial watch: DNA-based vaccines for oncological indications. 2017 , 6, e1398878		22
245	Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. 2017 , 117, 628-638		71
244	Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. 2017 , 14, 247-258		195
243	Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. 2017 , 37, 129-143		21
242	Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. 2017 , 36, 585-592		14
241	Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. 2017 , 6, e1258505		21
240	New insight into cancer immunotherapy. 2017 , 45 Suppl 1, 50-55		3
239	Immuntherapie in der Onkologie. 2017 , 12, 17-33		1
238	Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies. <i>Oncotarget</i> , 2017 , 8, 12374-12388	3-3	22
237	How cancer immunotherapy works. 2017 ,		
236	Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas. 2017 , 8, 1010		9
235	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. 2017 , 8, 1112		11
234	Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor. 2017 , 8, 1212		14
233	Dendritic Cells as Targets of Vaccines and Adjuvants. 2017 , 43-64		
232	The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cells. <i>Oncotarget</i> , 2017 , 8, 25525-25541	3-3	21
231	Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy. 2018 , 7, e1444412		7
230	Carbohydrate-based vaccines for oncotherapy. 2018 , 38, 1003-1026		47
229	Immunotherapy in Lung Cancer and the Role of Imaging. 2018 , 39, 314-321		2

228	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. 2018 , 52, 189-197	71
227	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. 2018 , 7, e1433982	23
226	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. 2018 , 231-246	
225	Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. 2018 , 39, 209-221	96
224	Thyroid dysfunctions secondary to cancer immunotherapy. 2018 , 41, 625-638	39
223	Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase. 2018 , 171, 198-206	63
222	Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model. 2018 , 15, 5098-5104	
221	Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress. 2018 , 233, 2928-2936	25
220	Systematic evaluation of cell-SELEX enriched aptamers binding to breast cancer cells. 2018 , 145, 53-62	32
219	Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. 2018 , 67, 89-100	23
218	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. 2018 , 23-39	5
217	Nouvelles perspectives dans l'immunothérapie des cancers pédiatriques. 2018 , 105 Suppl 1, S68-S79	2
216	Inmunología del cáncer I: bases moleculares y celulares de la respuesta inmune antitumoral. 2018 , 18, 80-89	2
215	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. 2018 , 2018, 8097398	7
214	Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. 2018 , 1, 193-208	3
213	Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. 2018 , 19,	65
212	Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. 2018 , 2018, 4325874	50
211	Trial watch: Peptide-based vaccines in anticancer therapy. 2018 , 7, e1511506	90

210	The hallmarks of successful anticancer immunotherapy. 2018 , 10,			260
209	Synergistic Suppression of Melanoma Growth by a Combination of Natural dsRNA and Panaxadiolsaponins. 2018 , 38, 378-387			1
208	Transcriptome evolution from breast epithelial cells to basal-like tumors. <i>Oncotarget</i> , 2018 , 9, 453-463	3.3		9
207	Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. 2018 , 128, 30-42			9
206	Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. 2018 , 7, e1484980			19
205	Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. 2018 , 67, 1285-1296			17
204	Colorectal cancer immunotherapy. 2018 , 533, 127-138			
203	Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines. 2018 , 9, 557			26
202	The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. <i>Frontiers in Oncology</i> , 2018 , 8, 27	5.3		46
201	A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future?. <i>Frontiers in Oncology</i> , 2018 , 8, 68	5.3		8
200	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). 2018 , 6, 39			202
199	Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. 2018 , 18, 601-618			275
198	Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multi-peptide vaccines: a case report. 2018 , 16, 23			17
197	Complement system's role in cancer and its therapeutic potential in ovarian cancer. 2018 , 88, e12672			12
196	Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines. 2018 , 36, 4171-4180			21
195	Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTTC-Like. 2019 , 104, 3557-3575			24
194	Immunotherapy in Ovarian Cancer. 2019 , 28, 447-464			17
193	Immunotherapy Summit: Proceedings and Identified Priorities for Safe Administration and Care. 2019 , 23, E60-E65			

192	The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. 2019 , 68, 1733-1745	23
191	WNT/ECatenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. 2019 , 10, 2293	76
190	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019 , 9, 1004	5.3 13
189	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1 485
188	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019 , 11,	6.6 18
187	Tumours pick the path to cancer inflammation. 2019 , 21, 1055-1057	1
186	A Reappraisal of Thymosin Alpha1 in Cancer Therapy. <i>Frontiers in Oncology</i> , 2019 , 9, 873	5.3 16
185	Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer. <i>Cancers</i> , 2019 , 11,	6.6 8
184	Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. <i>Cancers</i> , 2019 , 11,	6.6 14
183	OMIP-054: Broad Immune Phenotyping of Innate and Adaptive Leukocytes in the Brain, Spleen, and Bone Marrow of an Orthotopic Murine Glioblastoma Model by Mass Cytometry. 2019 , 95, 422-426	10
182	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. 2019 , 133, 181-193	30
181	Cancer in Older Adults. 2019 ,	
180	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. 2019 , 307, 108-138	26
179	Type I interferons and dendritic cells in cancer immunotherapy. 2019 , 348, 217-262	42
178	ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives. 2019 , 2019, 1732175	11
177	Control of multilayer biological networks and applied to target identification of complex diseases. 2019 , 20, 271	5
176	Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues. 2019 , 9, 8097	6
175	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. 2019 , 48, 3771-3810	179

174	Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. 2019 , 164, 119-188	22
173	Arginine, histidine and tryptophan: A new hope for cancer immunotherapy. 2019 , 8, 100149	7
172	Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. 2019 , 120, 871-882	38
171	Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review. 2019 , 137, 35-42	9
170	Efficacy of Cancer Immunotherapy: An Umbrella Review of Meta-analyses of Randomized Controlled Trials. <i>Cancers</i> , 2019 , 11,	6.6 5
169	Emerging Therapeutic Targets in Oncologic Photodynamic Therapy. 2018 , 24, 5268-5295	7
168	Production and Characterization of Glutathione-Chitosan Conjugate Films as Systems for Localized Release of Methotrexate. 2019 , 11,	2
167	WNT Signaling in Cancer Immunosurveillance. 2019 , 29, 44-65	102
166	Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15 - Implications for Clinical Trials. 2019 , 39, 107-112	7
165	Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models. 2019 , 1884, 297-315	31
164	Nanotechnology-based photoimmunological therapies for cancer. 2019 , 442, 429-438	47
163	Cancer Immunosurveillance. 2019 ,	2
162	Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes. 2019 , 25, 2155-2165	11
161	Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. 2019 , 29, 513-529	38
160	Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy. 2019 , 39, 1447-1484	15
159	Cell-intrinsic survival signals. The role of autophagy in metastatic dissemination and tumor cell dormancy. 2020 , 60, 28-40	10
158	Methods to assess DC-dependent priming of T cell responses by dying cells. 2020 , 632, 55-65	
157	Tumor-derived exosomes (TDEs): How to avoid the sting in the tail. 2020 , 40, 385-412	19

156	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2020 , 6, 29-49		9
155	Oncolytic Viruses. 2020 ,		0
154	Targeted cancer immunotherapy with genetically engineered oncolytic <i>Salmonella typhimurium</i> . 2020 , 469, 102-110		32
153	. 2020 ,		4
152	Microfluidics for Immuno-oncology. 2020 , 149-176		1
151	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. 2020 , 34, 21-34		74
150	Human NK-92 Cells Function as Target Cells for Human NK Cells - Implications for CAR NK-92 Therapies. 2020 , 40, 5355-5359		7
149	Colorectal Cancer Immunotherapy: Options and Strategies. 2020 , 11, 1624		52
148	Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. 2020 , 11, 577869		31
147	Tumor-related HSP70 released after cryo-thermal therapy targeted innate immune initiation in the antitumor immune response. 2020 , 37, 843-853		3
146	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. 2020 , 2020, 9235638		25
145	[Basic principles of immunotherapy]. 2020 , 60, 682-686		
144	Immunotherapy in Gastrointestinal Cancers. 2020 , 36, 231-237		2
143	Emerging Autophagy Functions Shape the Tumor Microenvironment and Play a Role in Cancer Progression - Implications for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020 , 10, 606436	5-3	20
142	Optimization of Liposomes for Antigen Targeting to Splenic CD169 Macrophages. 2020 , 12,		9
141	Necroptosis in Immuno-Oncology and Cancer Immunotherapy. 2020 , 9,		25
140	Personalized biomedicine in cancer: from traditional therapy to sustainable healthcare. 2020 , 441-457		
139	Chemokine biology on immune checkpoint-targeted therapies. 2020 , 137, 260-271		8

138	Targeting Mitochondrial Singlet Oxygen Dynamics Offers New Perspectives for Effective Metabolic Therapies of Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 573399	53	3
137	Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. 2020 , 21,		5
136	Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. 2020 , 9, 1757360		18
135	pH-Sensitive Carbon Dots for Enhancing Photomediated Antitumor Immunity. 2020 , 17, 2532-2545		8
134	The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. 2020 , 11, 940		113
133	Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report. 2020 , 12, 175-181		3
132	Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. 2020 , 8, 14		12
131	Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?. 2020 , 16, 1327-1330		2
130	Immuno-Oncology, Imaging Biomarkers and Response to Chemotherapy in Cancer Treatment. 2020 ,		
129	Cancer immunotherapy using T-cell receptor engineered T cell. 2020 , 5, 5-5		3
128	Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. 2020 , 8,		17
127	Regulation of Fas in response to bortezomib and epirubicin in colorectal cancer cells. 2020 , 32, 193-201		8
126	Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review. 2020 , 28, 714-726		5
125	Nanotechnologies for enhancing cancer immunotherapy. 2020 , 13, 2595-2616		14
124	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. 2020 , 10,		13
123	The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. 2020 , 50, 389-398		2
122	Recent progress in tumor photodynamic immunotherapy. 2020 , 31, 1709-1716		42
121	Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona. 2020 , 21,		8

120	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. 2020 , 9, 1703449	81
119	Immuntherapeutische Therapieansätze Ein Überblick. 2020 , 53, 216-223	
118	Cellular immunotherapies for cancer. 2021 , 190, 41-57	16
117	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. 2021 , 11, 1129-1147	15
116	Biomarkers for predicting the outcome of various cancer immunotherapies. 2021 , 157, 103161	5
115	Current progress in cancer immunotherapy based on natural killer cells. 2021 , 45, 2-17	2
114	Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. 2021 , 28, 100427	2
113	Two-dimensional biomaterials: material science, biological effect and biomedical engineering applications. 2021 , 50, 11381-11485	23
112	Prospect for application of mathematical models in combination cancer treatments. 2021 , 23, 100534	3
111	Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis. 2021 , 3, zcab005	0
110	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. 2021 , 329-350	
109	Platelet lysate: a promising candidate in regenerative medicine. 2021 , 16, 71-85	4
108	Industrial Perspective on Immunotherapy. 2021 , 1295, 327-347	
107	Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. 2021 , 13,	3
106	miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy. <i>Cancers</i> , 2021 , 13,	6.6 21
105	Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). 2021 , 21, 535	4
104	Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells. 2021 , 22,	2
103	Patient-Derived Organoids for Precision Cancer Immunotherapy. 2021 , 81, 3149-3155	13

102	Neoantigen: A New Breakthrough in Tumor Immunotherapy. 2021 , 12, 672356		21
101	Preclinical models and technologies to advance nanovaccine development. 2021 , 172, 148-182		3
100	The Immunotherapy Landscape in Adrenocortical Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
99	Vincristine attenuates cardiac fibrosis through the inhibition of NLRP3 inflammasome activation. 2021 , 135, 1409-1426		1
98	The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. 2021 , 22,		1
97	Macrophages as a "weapon" in anticancer cellular immunotherapy. 2021 , 37, 749-758		6
96	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. <i>Cancers</i> , 2021 , 13,	6.6	4
95	An immunotherapeutic approach to decipher the role of long non-coding RNAs in cancer progression, resistance and epigenetic regulation of immune cells. 2021 , 40, 242		2
94	Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. 2021 , 1, 2100010		2
93	Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy.. 2022 , 12, 92-106		6
92	Balance and modulation of immunoediting for cancer treatment using synergistic nano-photo-immuno effects. 2021 , 10, 3383-3389		
91	Emerging role of natural products in cancer immunotherapy.. 2022 , 12, 1163-1185		3
90	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. 2021 , 24, 101149		2
89	FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. 2021 ,		2
88	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. 2021 ,		3
87	Cellular Immunotherapy and the Lung. <i>Vaccines</i> , 2021 , 9,	5.3	3
86	The spontaneous remission of cancer: Current insights and therapeutic significance. 2021 , 14, 101166		7
85	T Cell Epitope Prediction and Its Application to Immunotherapy. 2021 , 12, 712488		0

84	Bacteria-based immune therapies for cancer treatment. 2021,		0
83	Cancer immune resistance: can theories converge?. 2017, 1, 411-419		9
82	The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. 2015, 10, e0138726		22
81	Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy. <i>Oncotarget</i> , 2017, 8, 40454-40468	3-3	21
80	Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 18192-205	3-3	85
79	A microfluidic approach towards hybridoma generation for cancer immunotherapy. <i>Oncotarget</i> , 2015, 6, 38764-76	3-3	15
78	The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. <i>Oncotarget</i> , 2016, 7, 1500-15	3-3	43
77	Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. <i>Oncotarget</i> , 2016, 7, 43604-43615	3-3	27
76	HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. 2017, 14, 4415-4427		42
75	Progress of immune checkpoint LAG-3 in immunotherapy. 2020, 20, 207		15
74	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. 2020, 14, 490		16
73	Topography of cancer-associated immune cells in human solid tumors. 2018, 7,		123
72	Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. 2019, 551-600		
71	Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models. 2020, 2058, 213-227		1
70	Immune-based Therapies-What the Emergency Physician Needs to Know. 2022, 40, 135-148		
69	Encyclopedia of Molecular Pharmacology. 2020, 1-7		
68	Th balance related host genetic background affects the therapeutic effects of combining carbon-ion radiotherapy with dendritic cell immunotherapy. 2021,		2
67	The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. 2021,		

66	Proof of Concept Study: Mesoporous Silica Nanoparticles, From Synthesis to Active Specific Immunotherapy. 2020 , 2,		1
65	Wilms' Tumor 1 (WT1): The Vaccine for Cancer. 2020 , 3, 165-171		0
64	A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?. 2015 , 7, 73-8		3
63	[A Reflection of the New Wave of Immunotherapy on the Clinical Study of ?Chinese Lung Cancer Immunotherapy]. 2017 , 20, 695-702		0
62	[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application]. 2017 , 20, 645-651		
61	Immune response evoked by tumor-associated NADH oxidase (tNOX) confers potential inhibitory effect on lung carcinoma in a mouse model. 2019 , 9, 740-751		1
60	Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2021 , 8, 713153	4.9	1
59	The Art of Oncoimmunovaccinomics. 2021 , 11, 50-66		0
58	Induced pluripotent stem cells-derived hematopoietic progenitors for cellular immunotherapies. 2022 , 233-263		0
57	Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition. 2021 , 7, eabi5790		5
56	Cancer Immunotherapy. 2021 , 404-410		
55	Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.. <i>ESMO Open</i> , 2021 , 7, 100340	6	0
54	Immuno-oncology trends: preclinical models, biomarkers, and clinical development.. 2022 , 10,		0
53	Cancer immunotherapy in adult patients with HIV.. <i>Journal of Investigative Medicine</i> , 2022 ,	2.9	
52	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.. <i>Life</i> , 2022 , 12,	3	3
51	Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy.. <i>Biosensors</i> , 2022 , 12,	5.9	2
50	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).. <i>European Journal of Immunology</i> , 2021 , 51, 2708-3145	6.1	12
49	Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2021 , 8, 713153	4.9	1

48	Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape.. <i>Expert Opinion on Drug Delivery</i> , 2022 ,	8	1
47	Review on Immuno-Oncology Agents for Cancer Therapy. <i>Research Journal of Pharmacology and Pharmacodynamics</i> , 2022 , 47-52	1.7	
46	Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022 , 12, 852194	5.3	0
45	Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF.. <i>Platelets</i> , 2022 , 1-5	3.6	
44	Characteristics of recent clinical investigations into systemic therapy against cervical cancer: systematic analysis of trial details from Clinicaltrials.gov.. <i>Journal of Obstetrics and Gynaecology</i> , 2021 , 1-9	1.3	
43	Autoimmunity regulation within the tumor microenvironment. 2022 , 51-71		
42	Review on Immuno-Oncology agents for Cancer Therapy. <i>Asian Journal of Pharmaceutical Research</i> , 2022 , 110-115	2.1	1
41	Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.. <i>ESMO Open</i> , 2022 , 7, 100446	6	1
40	image_1.jpeg. 2018 ,		
39	image_2.jpeg. 2018 ,		
38	table_1.PDF. 2018 ,		
37	table_2.PDF. 2018 ,		
36	Data_Sheet_1.PDF. 2020 ,		
35	image_1.PDF. 2018 ,		
34	image_2.PDF. 2018 ,		
33	image_3.PDF. 2018 ,		
32	image_4.PDF. 2018 ,		
31	image_5.PDF. 2018 ,		

30	image_6.PDF. 2018,		
29	image_7.PDF. 2018,		
28	image_8.PDF. 2018,		
27	table_1.xlsx. 2018,		
26	Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer.. <i>Cancers</i> , 2022, 14,	6.6	0
25	Estrogens, Cancer and Immunity.. <i>Cancers</i> , 2022, 14,	6.6	1
24	Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. <i>Vaccines</i> , 2022, 10, 816	5.3	2
23	Role of Adenoviruses in Cancer Therapy. <i>Frontiers in Oncology</i> , 12,	5.3	1
22	Biomarker Panels and Contemporary Practice in Clinical Trials of Personalized Medicine. 2022, 549-562		
21	Research Progress of LAG-3 Molecule in Non-Small Cell Lung Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 5990-5997	0	
20	Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy. <i>Advanced Science</i> , 220075613.6	3.6	2
19	Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era. <i>Journal of Cancer Research and Clinical Oncology</i> ,	4.9	0
18	Adverse Renal Effects of Anticancer Immunotherapy: A Review. 2022, 14, 4086		
17	Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer. 2022,		0
16	The Role of Immunotherapy in Pancreatic Cancer. 2022, 29, 6864-6892		1
15	The regulatory role of long non- coding RNAs as a novel controller of immune response against cancer cells.		1
14	Reprogramming M2-polarized patient-derived glioblastoma associated microglia/macrophages via CSF1R inhibition.		0
13	Cancer Gene Therapy. 1-11		0

12	Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. 2022 , 14, 2326	0
11	Immunoinformatics Analysis of Citrullinated Antigen as Potential Multi-peptide Lung Cancer Vaccine Candidates for Indonesian Population. 2022 , 28,	0
10	Adenovirus-Inspired Virus-like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses. 2022 , 10, 2881	0
9	The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy. 2022 , 1-14	0
8	Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects. 2022 , 10, 2011	3
7	Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. 2022 , 14, 5678	0
6	Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors. 2023 , 28, 2047	1
5	Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives. 2023 , 161, 114503	1
4	Tumor-infiltrating lymphocytes for melanoma immunotherapy. 2023 , 12,	0
3	PLGA Particles in Immunotherapy. 2023 , 15, 615	0
2	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. 2023 , 30, 2366-2387	0
1	Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen. 2023 , 14, 3501-3513	0